Thousand Oaks-based Amgen Inc. beat revenue expectations but issued lower full-year guidance in its second-quarter financial results.  

The biotech company’s revenue was $6.5 billion, a 5.2 percent increase compared to second-quarter 2020. The increase was driven by higher volume of sales, partially offset by lower net prices.  

Amgen’s adjusted earnings benefited from increased revenues and fewer average shares outstanding because of a share repurchase program. Adjusted net income increased 4 percent to $2.5 billion, or $4.38 per share. According to Refinitiv, analysts expected $4.10 per share on average.  


Join our Membership to get the full story.

Are you a current Member? Sign In